Integer price target raised to $150 from $145 at Truist

Truist raised the firm’s price target on Integer to $150 from $145 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results for the MedTech sector. While the firm believes that any hurricane related headwind call-outs for Q4 will generally get “a pass” from investors, it could cause companies with elective or deferrable procedure areas to see more muted guide increases, the analyst tells investors in a research note. For the stock, Truist contends that the company has scarcity value as a profitable SMID with a ‘steady-eddy’ growth/margin profile which should keep investors gravitating towards the name as long as organic revenue growth for medical segments continue trending in high single digits.